News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid Tumor IVD Kit
Natick, MA – October 24, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory
Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina
Enables content for newly launched Illumina MiSeq™ i100 and expands Illumina oncology panel portfolio to include targeted liquid biopsy panels Natick, MA – October 16, 2024
Pillar Biosciences Partners with AstraZeneca to Help Accelerate Access to Liquid Biopsy Testing
Partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians and patients through rapid, affordable, kitted NGS testing solutions. Natick, MA
Pillar Biosciences Launches oncoReveal™ Nexus To Help Accelerate the Delivery of Targeted Therapy
Natick, MA – August 27, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal™ Nexus, a research-use-only (RUO) next-generation sequencing (NGS)
Pillar Biosciences’ FDA Approved Solid Tumor NGS Kit oncoReveal™ CDx Launched at Molecular Pathology Laboratory Network, Inc.
Natick, MA – July 30, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced that Molecular Pathology Laboratory Network, Inc., (MPLN) is now the
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™Dx System
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing Natick, MA – April